GlaxoSmithKline is recalling the popular heartburn medicine Zantac in all markets, days after the US Food and Drug Administration (FDA) found “unacceptable” levels of probable cancer-causing impurity in the drug. Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Regulators have been recalling some blood pressure and heart failure medicines since last year. Britain’s medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines – a syrup, an injection and tablets of 150mg and 300mg dosages – over an potential carcinogen called N-nitrosodimethylamine (NDMA) Over-the-counter 75mg dosage Zantac products are produced by a different company and are not affected by the recall, it added. “GSK informed the MHRA [Medicines and Healthcare products Regulatory Agency] of our decision to suspend the release, distribution and supply of all dose forms of Zantac products,” a company spokesman confirmed to Reuters. Johnson & Johnson […]